Company: LNAI
Filing Date: 2025-09-29
Form Type: 10-K
Source: 0001731122-25-001316
Chunk: 1102

Company: Lunai Bioworks Inc.
Filing Date: 2025-09-29
Form: 10-K
Item: Item 1
Chunk 1102
---
 Tumors; specifically Pancreatic tumors

Allogeneic Cell Therapy Platform
– Completed pre-IND, IND-enabling phase.

1

Based
on learnings from our internal research, literature reviews of ongoing clinical development for solid tumors, and recent advances in immune
modulation, we have designed an innovative therapeutic vaccination platform that could potentially be used to induce life-long remission
from some of the deadliest solid tumors such as pancreatic, liver, triple negative breast and head & neck cancers.

The platform
may one day enable broad immune enhancements that are combined with cancer specific antigens that could be applicable to a wide range
of solid tumors. This approach allows us to quickly adapt our approach to any patient solid tumor using the same banked allogenic drug
substance.

RENB-DC20: Genetically modified Allogeneic Dendritic
Cell Therapeutic Vaccine as Potential Treatment Product for Long-term Remission of Triple Negative Breast Cancer

Triple Negative Breast Cancer
(TNBC) is a subtype of breast cancer that is negative for estrogens receptor (ER) negative, progesterone receptor (PR) negative and human
epidermal growth factor receptor 2 (HER2). TNBC is characterized by its unique molecular profile, aggressive nature, and distinct metastatic
patterns that lack targeted therapies. TNBC is well known for its aggressive behavior and is characterized by onset at a younger age,
high mean tumor size, and higher-grade tumors.

Based upon our internal research,
literature reviews of ongoing clinical development for solid tumors, and recent advances in immune modulation, we believe we may have
the ability to design an innovative therapeutic vaccination platform that could potentially be used to treat some of the deadliest and
hard-to-treat solid tumors that include triple negative breast cancer.

Renovaro Cube Overview

Renovaro Cube is an AI-driven
healthcare technology company focusing on the earliest possible detection of cancer and its recurrence. Renovaro Cube has developed a
proprietary AI platform that analyzes genetics using Explainable AI (as defined below) to provide earlier and more accurate cancer diagnosis.
This platform uses a multi-omics approach to search for individual biomarkers that are present even in asymptomatic patients. This approach
is combined with differential molecular capabilities that are designed to identify, differentiate and pinpoint the exact source. Renovaro
Cube’s process also involves the mining of biomarker panels, which are integrated into a machine learning library referred to as
“RenovaroCube” to further enhance diagnosis.